Trial · NCT05283395
Rocklatan® Evaluation
NCT05283395, Phase 4, Completed, Aerie Pharmaceuticals; results first posted 2024-04-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rocklatan® Evaluation. Trials, record NCT05283395. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05283395
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rocklatan® Evaluation
- NCT number
- NCT05283395
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 136 participants, actual
- Lead sponsor
- Aerie Pharmaceuticals
- Conditions
- Glaucoma
- Interventions
- Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
- First posted
- 2022-03-17
- Last updated
- 2024-04-03
- Results first posted
- 2024-04-03
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12 | Baseline (Day 0 pretreatment), Week 12 | IOP was measured using Goldmann applanation tonometry at the Baseline and Week 12 visits. One eye (study eye) contributed data to this analysis. A negative value indicates an improvement in IOP. No hypothesis testing was prespecified for this endpoint. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12 | Baseline (Day 0 pretreatment), Week 12 | All subjects that received at least 1 follow-up visit with a completed IOP measure and with complete data at both baseline and final visits. | percent change | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12 | Rocklatan (Latanoprost Mono) | -21.2 | Standard Deviation 17.46 | percent change | |
| Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12 | Rocklatan (Latanoprost +1) | -15.7 | Standard Deviation 21.91 | percent change | |
| Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12 | Rocklatan (Latanoprost +2) | -16.9 | Standard Deviation 17.31 | percent change | |
| Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12 | Rocklatan Total | -18.5 | Standard Deviation 18.96 | percent change |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Rocklatan (Latanoprost Mono) | 61 | |
| Overall Study | STARTED | Rocklatan (Latanoprost +1) | 45 | |
| Overall Study | STARTED | Rocklatan (Latanoprost +2) | 30 | |
| Overall Study | COMPLETED | Rocklatan (Latanoprost Mono) | 54 | |
| Overall Study | COMPLETED | Rocklatan (Latanoprost +1) | 37 | |
| Overall Study | COMPLETED | Rocklatan (Latanoprost +2) | 25 | |
| Overall Study | NOT COMPLETED | Rocklatan (Latanoprost Mono) | 7 | |
| Overall Study | NOT COMPLETED | Rocklatan (Latanoprost +1) | 8 | |
| Overall Study | NOT COMPLETED | Rocklatan (Latanoprost +2) | 5 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Conjunctival hyperaemia | Eye disorders | Rocklatan (Latanoprost Mono) | 9 | 61 | |
| other | Conjunctival hyperaemia | Eye disorders | Rocklatan (Latanoprost +1) | 10 | 45 | |
| other | Conjunctival hyperaemia | Eye disorders | Rocklatan (Latanoprost +2) | 6 | 30 | |
| serious | Femur fracture | Injury, poisoning and procedural complications | Rocklatan (Latanoprost Mono) | 0 | 61 | |
| serious | Femur fracture | Injury, poisoning and procedural complications | Rocklatan (Latanoprost +1) | 0 | 45 | |
| serious | Femur fracture | Injury, poisoning and procedural complications | Rocklatan (Latanoprost +2) | 1 | 30 |
Source ClinicalTrials.gov
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Rocklatan (Latanoprost Mono) | 0 | 61 |
| Total, all-cause mortality | Rocklatan (Latanoprost +1) | 0 | 45 |
| Total, all-cause mortality | Rocklatan (Latanoprost +2) | 0 | 30 |
| Total, other adverse events | Rocklatan (Latanoprost Mono) | 9 | 61 |
| Total, other adverse events | Rocklatan (Latanoprost +1) | 10 | 45 |
| Total, other adverse events | Rocklatan (Latanoprost +2) | 6 | 30 |
| Total, serious adverse events | Rocklatan (Latanoprost Mono) | 0 | 61 |
| Total, serious adverse events | Rocklatan (Latanoprost +1) | 0 | 45 |
| Total, serious adverse events | Rocklatan (Latanoprost +2) | 1 | 30 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05283395
GET https://conductscience.org/api/trials/v1/NCT05283395/registered